TY - JOUR
T1 - PDP type brain tumor in association with multiple endocrine neoplasia type 1
AU - Einarsson, Halldór Bjarki
AU - Frederiksen, Anja Lisbeth
AU - Pedersen, Inge Soekilde
AU - Ettrup, Marianne Schmidt
AU - Wirenfeldt, Martin
AU - Boldt, Henning
AU - Nguyen, Nina
AU - Andersen, Marianne Skovsager
AU - Bjarkam, Carsten Reidies
AU - Poulsen, Frantz Rom
N1 - Publisher Copyright:
© 2024 The Authors
PY - 2024/3/30
Y1 - 2024/3/30
N2 - Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant syndrome caused by inactivating pathogenic variants in the tumor suppressor gene menin 1 on chromosome 11q13 (Falchetti et al., 2009). The syndrome is characterized by neoplasia in two or more endocrine glands and has a high degree of penetrance. Pathogenic germline multiple neoplasia type 1 variants primarily result in neoplasia affecting the parathyroid glands, the pancreatic islet cells, and the anterior pituitary in combination. Primary hyperparathyroidism is the most common pathological manifestation of the syndrome, followed by pancreatic neuroendocrine tumors. Important genetic confirmation has been provided showing that ependymoma should be considered as a neoplasm that can occur in patients with MEN1 (Kato et al., 1996; Cuevas-Ocampo et al., 2017). The biphasic histopathological tumor entity shown in the present case we name Pleomorphic Xanthoastocytoma grade 3 differential pathology (PDP) in association with Multiple Endocrine Neoplasia type 1. This MEN1 associated tumor subtype is an extension of the findings on MEN1 associated ependymoma, where we show that the clinical phenotype itself may potentially be triggered by a frameshift germline pathogenic variant for the MEN1 gene, in combination with cyclin-dependent kinase inhibitor 1B gene germline variant and cyclin dependent kinase inhibitor 2A somatic deletion downstream of menin.
AB - Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant syndrome caused by inactivating pathogenic variants in the tumor suppressor gene menin 1 on chromosome 11q13 (Falchetti et al., 2009). The syndrome is characterized by neoplasia in two or more endocrine glands and has a high degree of penetrance. Pathogenic germline multiple neoplasia type 1 variants primarily result in neoplasia affecting the parathyroid glands, the pancreatic islet cells, and the anterior pituitary in combination. Primary hyperparathyroidism is the most common pathological manifestation of the syndrome, followed by pancreatic neuroendocrine tumors. Important genetic confirmation has been provided showing that ependymoma should be considered as a neoplasm that can occur in patients with MEN1 (Kato et al., 1996; Cuevas-Ocampo et al., 2017). The biphasic histopathological tumor entity shown in the present case we name Pleomorphic Xanthoastocytoma grade 3 differential pathology (PDP) in association with Multiple Endocrine Neoplasia type 1. This MEN1 associated tumor subtype is an extension of the findings on MEN1 associated ependymoma, where we show that the clinical phenotype itself may potentially be triggered by a frameshift germline pathogenic variant for the MEN1 gene, in combination with cyclin-dependent kinase inhibitor 1B gene germline variant and cyclin dependent kinase inhibitor 2A somatic deletion downstream of menin.
KW - Cyclin-dependent kinase inhibitor
KW - Ependymoma
KW - Multiple endocrine neoplasia type 1
KW - Pleomorphic xanthoastrocytoma
U2 - 10.1016/j.heliyon.2024.e27418
DO - 10.1016/j.heliyon.2024.e27418
M3 - Journal article
C2 - 38510015
AN - SCOPUS:85187719935
SN - 2405-8440
VL - 10
JO - Heliyon
JF - Heliyon
IS - 6
M1 - e27418
ER -